The Effect of Resveratrol dose and Duration of Treatment on Blood Pressure in Patients with Cardiovascular Disorders: A Systematic Review

Author(s): Fahimeh D. Mashhadi, Roshanak Salari, HamidReza Ghorbanzadeh*

Journal Name: Current Drug Discovery Technologies

Volume 17 , Issue 3 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Objective: Hypertension is an important risk factor that causes many deaths in the world every year. Researchers continue to undertake studies to find an effective drug for reducing blood pressure. One of the phytochemicals that recently attracted the attention of researchers is resveratrol-polyphenol, found in grapes. The purpose of this systematic review is to investigate the effect of resveratrol as a cardioprotective agent effective in reducing hypertension in patients with hypertension.

Methods: Studies and clinical articles from databases Scopus, Pubmed, Ovid and Cochrane have been collected until September 2017; the keywords are Blood Pressure, Hypertension, Hypertensive, Cardiovascular, and Resveratrol.

Results: Data from five studies with a total of 229 hypertensive and pre-hypertensive patients (men and women) showed that resveratrol plays an important role in reducing blood pressure.

Conclusion: Resveratrol appears to have anti-hypertensive effects, depending on the dose and duration of treatment. Researchers attribute one of the important blood pressure reducing mechanisms of resveratrol to increasing levels of NO. Based on the results of this systematic review, it is suggested that more clinical studies be conducted to find the appropriate dose and duration of treatment.

Keywords: Hypertension, blood pressure, cardiovascular, resveratrol, blood pressure, AMPK.

[1]
Go ASBM, King SMC, Fonarow GC, Lawrence W, Williams KA. Sancheze. An effective approach to high blood pressure control. Hypertension 2014; 63: 878-85.
[http://dx.doi.org/10.1161/HYP.0000000000000003] [PMID: 24243703]
[2]
Kochanek KDMS, Murphy SL, Xu J. Deaths: Final Data for 2011. Natl Vital Stat Rep 2015; 63(3): 1-120.
[PMID: 26222597]
[3]
Whelton PK, He J, Muntner P. Prevalence, awareness, treatment and control of hypertension in North America, North Africa and Asia. In: Nature Publishing Group. 2004; Vol. 18: pp. 545-1.
[4]
Hamza SM, Dyck JR. Systemic and renal oxidative stress in the pathogenesis of hypertension: modulation of long-term control of arterial blood pressure by resveratrol. Front Physiol 2014; 5: 292.
[http://dx.doi.org/10.3389/fphys.2014.00292] [PMID: 25140155]
[5]
Go AS, Mozaffarian D, Roger VL, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation 2014; 129(3): e28-e292.
[http://dx.doi.org/10.1161/01.cir.0000441139.02102.80] [PMID: 24352519]
[6]
Houston M. Nutrition and Nutraceutical supplements for the treatment of hypertension: Part III Wiley Online Library 15: 931-7.
[7]
Liu Y, Ma W, Zhang P, He S, Huang D. Effect of resveratrol on blood pressure: a meta-analysis of randomized controlled trials. Clin Nutr 2015; 34(1): 27-34.
[http://dx.doi.org/10.1016/j.clnu.2014.03.009] [PMID: 24731650]
[8]
Panagiotakos DB, Pitsavos C, Arvaniti F, Stefanadis C. Adherence to the Mediterranean food pattern predicts the prevalence of hypertension, hypercholesterolemia, diabetes and obesity, among healthy adults; the accuracy of the MedDietScore. Prev Med 2007; 44(4): 335-40.
[http://dx.doi.org/10.1016/j.ypmed.2006.12.009] [PMID: 17350085]
[9]
Arts ICW, Hollman PCH. Polyphenols and disease risk in epidemiologic studies. Am J Clin Nutr 2005; 81(1)(Suppl.): 317S-25S.
[http://dx.doi.org/10.1093/ajcn/81.1.317S] [PMID: 15640497]
[10]
Renaud S, de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992; 339(8808): 1523-6.
[http://dx.doi.org/10.1016/0140-6736(92)91277-F] [PMID: 1351198]
[11]
Bravo L. Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 1998; 56(11): 317-33.
[http://dx.doi.org/10.1111/j.1753-4887.1998.tb01670.x] [PMID: 9838798]
[12]
Pérez-Jiménez J, Saura-Calixto F. Grape products and cardiovascular disease risk factors. Nutr Res Rev 2008; 21(2): 158-73.
[http://dx.doi.org/10.1017/S0954422408125124] [PMID: 19087369]
[13]
Carrizzo A, Forte M, Damato A, et al. Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem Toxicol 2013; 61: 215-26.
[http://dx.doi.org/10.1016/j.fct.2013.07.021] [PMID: 23872128]
[14]
Pollack RM, Crandall JP. Resveratrol: therapeutic potential for improving cardiometabolic health. Am J Hypertens 2013; 26(11): 1260-8.
[http://dx.doi.org/10.1093/ajh/hpt165] [PMID: 24025725]
[15]
Magyar K, Halmosi R, Palfi A, et al. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc 2012; 50(3): 179-87.
[http://dx.doi.org/10.3233/CH-2011-1424] [PMID: 22240353]
[16]
Rakesh O, Pranesh K, Bhavin V. A randomized active controlled clinical study to evaluate efficacy and safety of resveratrol as an adjuvant therapy in patients with hypertension. Asian Journal of Pharmaceutical and Clinical Research 10(1): 376-9.
[17]
Spaak J, Merlocco AC, Soleas GJ, et al. Dose-related effects of red wine and alcohol on hemodynamics, sympathetic nerve activity, and arterial diameter. Am J Physiol Heart Circ Physiol 2008; 294(2): H605-12.
[http://dx.doi.org/10.1152/ajpheart.01162.2007] [PMID: 18055508]
[18]
Wong RHX, Howe PRC, Buckley JD, Coates AM, Kunz I, Berry NM. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr Metab Cardiovasc Dis 2011; 21(11): 851-6.
[http://dx.doi.org/10.1016/j.numecd.2010.03.003] [PMID: 20674311]
[19]
Theodotou M, Fokianos K, Mouzouridou A, et al. The effect of resveratrol on hypertension: A clinical trial. Exp Ther Med 2017; 13(1): 295-301.
[http://dx.doi.org/10.3892/etm.2016.3958] [PMID: 28123505]
[20]
Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42(6): 1206-52.
[http://dx.doi.org/10.1161/01.HYP.0000107251.49515.c2] [PMID: 14656957]
[21]
Nonomura S, Kanagawa H, Makimoto A. Chemical constituents of polygonaceous plants. i. studies on the components of ko-j o-kon.(polygonum cuspidatum sieb. et zucc.). Yakugaku Zasshi 1963; 83: 988-90.
[http://dx.doi.org/10.1248/yakushi1947.83.10_988] [PMID: 14089847]
[22]
He S, Sun C, Pan Y. Red wine polyphenols for cancer prevention. Int J Mol Sci 2008; 9(5): 842-53.
[http://dx.doi.org/10.3390/ijms9050842] [PMID: 19325788]
[23]
Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5(6): 493-506.
[http://dx.doi.org/10.1038/nrd2060] [PMID: 16732220]
[24]
Galié N, Manes A, Branzi A. The endothelin system in pulmonary arterial hypertension. Cardiovasc Res 2004; 61(2): 227-37.
[http://dx.doi.org/10.1016/j.cardiores.2003.11.026] [PMID: 14736539]
[25]
Merta M, Reiterová J, Rysavá R, et al. Role of endothelin and nitric oxide in the pathogenesis of arterial hypertension in autosomal dominant polycystic kidney disease. Physiol Res 2003; 52(4): 433-7.
[PMID: 12899655]
[26]
Brands MW, Fitzgerald SM. Blood pressure control early in diabetes: a balance between angiotensin II and nitric oxide. Clin Exp Pharmacol Physiol 2002; 29(1-2): 127-31.
[http://dx.doi.org/10.1046/j.1440-1681.2002.03619.x] [PMID: 11906471]
[27]
Touyz RM, Tabet F, Schiffrin EL. Redox-dependent signalling by angiotensin II and vascular remodelling in hypertension. Clin Exp Pharmacol Physiol 2003; 30(11): 860-6.
[http://dx.doi.org/10.1046/j.1440-1681.2003.03930.x] [PMID: 14678251]
[28]
Liu Z, Song Y, Zhang X, et al. Effects of trans-resveratrol on hypertension-induced cardiac hypertrophy using the partially nephrectomized rat model. Clin Exp Pharmacol Physiol 2005; 32(12): 1049-54.
[PMID: 16445570]
[29]
Dorri Mashhadi F, Zavvar Reza J, Jamhiri M, Hafizi Z, Zare Mehrjardi F, Safari F. The effect of resveratrol on angiotensin II levels and the rate of transcription of its receptors in the rat cardiac hypertrophy model. J Physiol Sci 2017; 67(2): 303-9.
[http://dx.doi.org/10.1007/s12576-016-0465-0] [PMID: 27324786]
[30]
Das M, Das DK. Resveratrol and cardiovascular health. Mol Aspects Med 2010; 31(6): 503-12.
[http://dx.doi.org/10.1016/j.mam.2010.09.001] [PMID: 20837050]
[31]
Miatello R, Vázquez M, Renna N, Cruzado M, Zumino AP, Risler N. Chronic administration of resveratrol prevents biochemical cardiovascular changes in fructose-fed rats. Am J Hypertens 2005; 18(6): 864-70.
[http://dx.doi.org/10.1016/j.amjhyper.2004.12.012] [PMID: 15925749]
[32]
Haddad JJ. Antioxidant and prooxidant mechanisms in the regulation of redox(y)-sensitive transcription factors. Cell Signal 2002; 14(11): 879-97.
[http://dx.doi.org/10.1016/S0898-6568(02)00053-0] [PMID: 12220615]
[33]
Dolinsky VW, Chakrabarti S, Pereira TJ, et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 2013; 1832(10): 1723-33.
[http://dx.doi.org/10.1016/j.bbadis.2013.05.018] [PMID: 23707558]
[34]
Török J. Participation of nitric oxide in different models of experimental hypertension. Physiol Res 2008; 57(6): 813-25.
[PMID: 19154086]
[35]
de la Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens 2010; 24(6): 373-9.
[http://dx.doi.org/10.1038/jhh.2009.91] [PMID: 19960026]
[36]
Chen Z-P, Mitchelhill KI, Michell BJ, et al. AMP-activated protein kinase phosphorylation of endothelial NO synthase. FEBS Lett 1999; 443(3): 285-9.
[http://dx.doi.org/10.1016/S0014-5793(98)01705-0] [PMID: 10025949]
[37]
Zhang J, Xie Z, Dong Y, Wang S, Liu C, Zou M-H. Identification of nitric oxide as an endogenous activator of the AMP-activated protein kinase in vascular endothelial cells. J Biol Chem 2008; 283(41): 27452-61.
[http://dx.doi.org/10.1074/jbc.M802578200] [PMID: 18693249]
[38]
Zordoky BNM, Robertson IM, Dyck JRB. Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim Biophys Acta 2015; 1852(6): 1155-77.
[http://dx.doi.org/10.1016/j.bbadis.2014.10.016] [PMID: 25451966]
[39]
Arunachalam G, Yao H, Sundar IK, Caito S, Rahman I. SIRT1 regulates oxidant- and cigarette smoke-induced eNOS acetylation in endothelial cells: Role of resveratrol. Biochem Biophys Res Commun 2010; 393(1): 66-72.
[http://dx.doi.org/10.1016/j.bbrc.2010.01.080] [PMID: 20102704]
[40]
Csiszar A, Labinskyy N, Pinto JT, et al. Resveratrol induces mitochondrial biogenesis in endothelial cells. Am J Physiol Heart Circ Physiol 2009; 297(1): H13-20.
[http://dx.doi.org/10.1152/ajpheart.00368.2009] [PMID: 19429820]
[41]
Carrizzo A, Puca A, Damato A, et al. Resveratrol improves vascular function in patients with hypertension and dyslipidemia by modulating NO metabolism. Hypertension 2013; 62(2): 359-66.
[http://dx.doi.org/10.1161/HYPERTENSIONAHA.111.01009] [PMID: 23753407]
[42]
Dong Q, Wu Z, Li X, et al. Resveratrol ameliorates cardiac dysfunction induced by pressure overload in rats via structural protection and modulation of Ca(2+) cycling proteins. J Transl Med 2014; 12(1): 323.
[http://dx.doi.org/10.1186/s12967-014-0323-x] [PMID: 25425099]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 17
ISSUE: 3
Year: 2020
Page: [325 - 331]
Pages: 7
DOI: 10.2174/1570163816666190226100812
Price: $65

Article Metrics

PDF: 20
HTML: 1